MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Pipeline Pivot | Explore MacroGenics' strategic shift following the discontinuation of vobra duo, refocusing efforts on promising candidates lorigerlimab and MGC026 |
Financial Tightrope | Delve into MacroGenics' financial balancing act, maintaining a cash runway into 2026 while facing negative EPS projections and market volatility |
Competitive Landscape | Uncover the challenges MacroGenics faces in a crowded oncology market, with upcoming data readouts crucial for differentiation |
Future Catalysts | Analyst price targets range from $3 to $8, with key milestones including Phase 2 data for lorigerlimab and potential strategic partnerships shaping outlook |
Metrics to compare | MGNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMGNXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.9x | −2.6x | −0.5x | |
PEG Ratio | 0.01 | −0.14 | 0.00 | |
Price/Book | 1.3x | 0.8x | 2.6x | |
Price / LTM Sales | 0.7x | 38.8x | 3.3x | |
Upside (Analyst Target) | 82.9% | 224.9% | 45.1% | |
Fair Value Upside | Unlock | 32.0% | 7.4% | Unlock |